Evidence map›Paper›PMID 38164067›Full record

ArticleCancer medicine2024

Drug-induced pneumonitis risk in diffuse large B-cell/follicular lymphoma patients treated with R-CHOP-like regimen is associated with the use of granulocyte colony-stimulating growth factors.

Elina Kaprio, Roosa Prusila, Susanna Tokola, Milla E L Kuusisto, Esa Jantunen, Hanne Kuitunen, Taina Turpeenniemi-Hujanen, Outi Kuittinen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Elina KaprioFaculty of Health Medicine, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.ORCID 0000-0003-0568-7422
Roosa PrusilaDepartment of Pediatrics, Kuopio University Hospital, Kuopio, Finland.
Susanna TokolaDepartment of Oncology and Radiotherapy, Medical Research Center, Oulu University Hospital, Oulu, Finland.ORCID 0000-0001-6326-5979
Milla E L KuusistoTranslational Medicine Research Unit, University of Oulu, Oulu, Finland.
Esa JantunenThe North Karelia Central Hospital, Joensuu, Finland.
Hanne KuitunenDepartment of Oncology and Radiotherapy, Medical Research Center, Oulu University Hospital, Oulu, Finland.
Taina Turpeenniemi-HujanenDepartment of Oncology and Radiotherapy, Medical Research Center, Oulu University Hospital, Oulu, Finland.
Outi KuittinenFaculty of Health Medicine, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.ORCID 0000-0001-9969-0053
Oulu University Hospital · FINorth Karelia Central Hospital · FIUniversity of Eastern Finland · FIKuopio University Hospital · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRituximab-based combinations are the standard of care in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Despite being on market for over 20 years, some of the adverse effects associated with the use of rituximab are not well known. Drug-induced interstitial pneumonitis (DIP) is a potentially fatal complication of the treatment. Granulocyte colony-stimulating factors (G-CSF) are supportive agents commonly used to prevent neutropenic infections. G-CSF are reported to have pulmonary toxicity, but the risk of DIP is greater when used in combination with other potentially pulmotoxic agents.

methodsIn this retrospective study, we reported the G-CSF use and risk of DIP in 234 DLBCL patients and 87 FL patients receiving R-CHOP-type immunochemotherapy.

resultsIn 72% of patients, the treatment included a G-CSF support. The overall incidence of treatment-induced pneumonitis was 6.9% in this patient group. All the DIP cases (n = 16) were among patients receiving G-CSF support (p = 0.03). Older age (over 60 years) and higher disease stage (Ann Arbor 3-4) also increased the risk of DIP.

conclusionsThese findings suggest that the use of G-CSF increases the risk of DIP, when used in combination with rituximab-containing regimen.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDoxorubicinGranulocyte Colony-Stimulating FactorLymphoma, FollicularLymphoma, Large B-Cell, DiffusePrednisoneRituximabVincristineAdultAgedAged, 80 and overFemaleHumansLung Diseases, InterstitialMaleCyclophosphamideDoxorubicinGranulocyte Colony-Stimulating FactorPrednisoneR-CHOP protocolRituximabVincristinediffuse large B‐cell lymphomadrug‐induced pneumonitisfollicular lymphomagranulocyte colony‐stimulating factors

Identifiers

PMID38164067
PMCPMC10807566
OpenAlexW4390503502

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.